^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IMA950

    i
    Associations
    News

    Trials

    Company:
    Cancer Research UK, Immatics, University Hospitals of Geneva
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma (IMA950-106) (NCT03665545)
    Phase 1/2
    University Hospital, Geneva
    Active, not recruiting
    Last update posted :
    12/26/2022
    Initiation :
    10/25/2018
    Primary completion :
    12/31/2023
    Completion :
    12/31/2023
    PD-L1
    |
    HLA-A*02:01
    |
    Keytruda (pembrolizumab) • Hiltonol (poly-ICLC) • IMA950
    Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (CRUK-CR0902-11) (NCT01222221)
    Phase 1
    Cancer Research UK
    Completed
    Last update posted :
    10/14/2015
    Initiation :
    07/01/2010
    Primary completion :
    02/01/2015
    Completion :
    02/01/2015
    MGMT • HLA-A • CSF2
    |
    HLA-A*02 • HLA-A2 positive
    |
    temozolomide • IMA950 • Leukine (sargramostim)